Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for prevention of acute kidney injury in children with pneumonia in the PICU
IRCT20180301038909N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetylcysteine in pneumonia (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Incidence of acute kidney injury, Serum creatinine change and 1 more. Started Jul 2026; status: completed.
02
Drugs
acetylcysteine
03
Conditions
pneumonia
Beyond the preview
Go deeper on IRCT20180301038909N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180301038909N1.